Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
acetyl-Ala-4-nitroanilide + H2O
acetyl-Ala + 4-nitroaniline
-
-
-
ir
actin + H2O
?
-
degradation at pH 4.0
-
?
Ala-4-methylcoumaryl-7-amide + H2O
Ala + 7-amino-4-methylcoumarin
-
-
-
ir
alpha-N-benzoyl-DL-Arg-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-Arg + beta-naphthylamine
-
-
-
?
alpha-N-benzoyl-DL-arginine-2-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + 2-naphthylamine
-
-
-
-
?
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
alpha-neoendorphin + H2O
?
-
preferentially aminopeptidase activity, endoeptidase activity after prolonged incubation
-
?
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
Arg-7-amido-4-methylcoumarin + H2O
L-arginine + 7-amino-4-methylcoumarin
Arg-7-amido-4-trifluoromethylcoumarin + H2O
Arg + 7-amino-4-trifluoromethylcoumarin
fluorogenic cathepsin H substrate
-
-
?
azocasein + H2O
?
-
-
-
-
ir
benzoyl-Arg-4-methylcoumaryl-7-amide + H2O
benzoyl-Arg + 7-amino-4-methylcoumarin
-
-
-
ir
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
benzoyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzoyl-L-Phe-L-Val-L-Arg-4-methylcoumaryl-7-amide + H2O
benzoyl-L-Phe-L-Val-L-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Pro-Ala-Ala-Ala-Pro + H2O
benzyloxycarbonyl-Pro-Ala-Ala-Ala + Pro
-
-
-
ir
benzyloxycarbonyl-Pro-Ala-Ala-Ala-Pro-NH2 + H2O
benzyloxycarbonyl-Pro-Ala-Ala-Ala + Pro-NH2
-
-
-
ir
bone morphogenetic protein 4 + H2O
?
-
-
-
-
?
bradykinin + H2O
?
-
no aminopeptidase activity, endopeptidase activity after prolonged incubation
-
?
citrulline-4-methylcoumaryl-7-amide + H2O
citrulline + 7-amino-4-methylcoumarin
-
-
-
ir
demorphin + H2O
?
-
no aminopeptidase activity, endopeptidase activity after prolonged incubation
-
?
dynorphin(1-13) + H2O
?
-
preferentially aminopeptidase activity, endoeptidase activity after prolonged incubation
-
?
dynorphin(1-6) + H2O
?
-
preferentially aminopeptidase activity, endoeptidase activity after prolonged incubation
-
?
Fibronectin + H2O
?
-
-
-
?
Gly-beta-naphthylamide + H2O
Gly + beta-naphthylamine
-
very poor substrate
-
?
H2N-Arg-7-amido-4-methylcoumarin + H2O
H2N-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Ala-beta-naphthylamide + H2O
L-Ala + beta-naphthylamine
-
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
-
-
?
L-Arg-4-methylcoumaryl-7-amide + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
L-Arg-beta-naphthylamide + H2O
L-Arg + beta-naphthylamine
-
-
-
?
L-Leu-2-naphthylamide + H2O
L-Leu + 2-naphthylamine
L-Leu-beta-naphthylamide + H2O
L-Leu + beta-naphthylamine
-
-
-
?
L-leucyl-2-naphthylamide + H2O
L-leucine + 2-naphthylamine
-
-
-
-
?
L-Lys-7-amido-4-methylcoumarin + H2O
L-Lys + 7-amino-4-methylcoumarin
L-Lys-beta-naphthylamide + H2O
L-Lys + beta-naphthylamine
-
-
-
?
L-Met-beta-naphthylamide + H2O
L-Met + beta-naphthylamine
-
-
-
?
L-Pro-beta-naphthylamide + H2O
L-Pro + beta-naphthylamine
-
very poor substrate
-
?
L-Ser-beta-naphthylamide + H2O
L-Ser + beta-naphthylamine
-
-
-
?
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
Leu-2-naphthylamide + H2O
leucine + 2-naphthylamine
-
-
-
?
Leu-4-methylcoumaryl-7-amide + H2O
Leu + 7-amino-4-methylcoumarin
-
-
-
ir
Leu-enkephalin + H2O
?
-
preferentially aminopeptidase activity, endoeptidase activity after prolonged incubation
-
?
Lys-4-methylcoumaryl-7-amide + H2O
Lys + 7-amino-4-methylcoumarin
-
-
-
ir
Lys-Arg-(Met)enkephalin + H2O
Lys-Arg + (Met)enkephalin
Lys-bradykinin + H2O
?
-
preferentially aminopeptidase activity, endoeptidase activity after prolonged incubation
-
?
Lys-Lys-(Met)enkephalin + H2O
Lys-Lys + (Met)enkephalin
Met-2-naphthylamide + H2O
Met + 2-naphthylamine
-
189% activity of substrate Leu-2-N-naphthylamine
-
ir
myofibrillar protein + H2O
?
-
-
-
-
?
myosin heavy chain + H2O
?
-
degradation at pH 4.0
-
?
neurotensin + H2O
?
-
no aminopeptidase activity, endopeptidase activity after prolonged incubation
-
?
pro-granzyme B + H2O
granzyme B + ?
-
cathepsin H has pro-granzyme B convertase activity in vitro
-
-
?
pro-surfactant protein B-EGFP fusion protein + H2O
?
-
cleavage 13 amino acids upstream of the NH2-terminus of mature surfactant protein B, and at the boundary between surfactant protein and C-terminal peptide
-
-
?
succinyl-Ala-Ala-4-nitroanilide + H2O
succinyl-Ala-Ala + 4-nitroaniline
-
-
-
ir
succinyl-Ala-Ala-Ala-4-nitroanilide + H2O
succinyl-Ala-Ala-Ala + 4-nitroaniline
-
-
-
ir
succinyl-Ala-Ala-Ala-Ala-4-nitroanilide + H2O
succinyl-Ala-Ala-Ala-Ala + 4-nitroaniline
-
-
-
ir
succinyl-Ala-Ala-Ala-Ala-Ala-4-nitroanilide + H2O
succinyl-Ala-Ala-Ala-Ala-Ala + 4-nitroaniline
-
-
-
ir
succinyl-Ala-Ala-Pro-4-nitroanilide + H2O
succinyl-Ala-Ala-Pro + 4-nitroaniline
-
-
-
ir
succinyl-Ala-Pro-Ala-4-nitroanilide + H2O
succinyl-Ala-Pro-Ala + 4-nitroaniline
-
-
-
ir
succinyl-Pro-Ala-Ala-4-nitroanilide + H2O
succinyl-Pro-Ala-Ala + 4-nitroaniline
-
-
-
ir
surfactant protein B + H2O
?
-
-
-
-
?
talin + H2O
?
-
cathepsin H cleaves the N-terminus of the talin F0 head domain
-
-
?
tropomyosin + H2O
?
-
degradation at pH 4.0
-
?
troponin I + H2O
?
-
degradation at pH 4.0, little degradation at pH 5.o-5.6
-
?
VALSLKISIGNVVKTMQFEPST + H2O
?
-
the peptide mimicks the N-terminus of the talin F0 head domain
-
-
?
Z-L-Phe-L-Arg-4-methylcoumaryl-7-amide + H2O
?
-
no substrate for wild type enzyme, endopeptidase activity of mutant T11_E18del-cathepsin H
-
?
Z-L-Phe-L-Arg-4-methylcoumaryl-7-amide + H2O
benzoyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
additional information
?
-
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O

alpha-N-benzoyl-DL-arginine + beta-naphthylamine
-
-
-
ir
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
-
-
-
-
?
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
-
-
-
ir
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
-
-
-
ir
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
-
-
-
-
?
Arg-2-naphthylamide + H2O

Arg + 2-naphthylamine
-
97% activity of substrate Leu-2-N-naphthylamine
-
ir
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
-
-
-
ir
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
-
-
-
ir
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
-
-
-
ir
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
-
-
-
ir
Arg-4-methylcoumaryl-7-amide + H2O

Arg + 7-amino-4-methylcoumarin
-
-
-
ir
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
?
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
conventional test substrate
-
ir
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
ir
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
conventional test substrate
-
ir
Arg-7-amido-4-methylcoumarin + H2O

L-arginine + 7-amino-4-methylcoumarin
-
-
-
-
?
Arg-7-amido-4-methylcoumarin + H2O
L-arginine + 7-amino-4-methylcoumarin
-
assay at pH 5.5, 37ưC
-
-
?
benzoyl-DL-Arg-2-naphthylamide + H2O

benzoyl-DL-Arg + 2-naphthylamine
-
-
-
-
?
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
-
-
-
ir
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
-
-
-
ir
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
-
-
-
ir
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
-
-
-
ir
benzoyl-L-Phe-L-Val-L-Arg-4-methylcoumaryl-7-amide + H2O

benzoyl-L-Phe-L-Val-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzoyl-L-Phe-L-Val-L-Arg-4-methylcoumaryl-7-amide + H2O
benzoyl-L-Phe-L-Val-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O

L-Arg + 7-amino-4-methylcoumarin
-
best substrate
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
best substrate
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
specific substrate
-
-
?
L-Leu-2-naphthylamide + H2O

L-Leu + 2-naphthylamine
-
-
-
-
?
L-Leu-2-naphthylamide + H2O
L-Leu + 2-naphthylamine
-
-
-
-
?
L-Lys-7-amido-4-methylcoumarin + H2O

L-Lys + 7-amino-4-methylcoumarin
-
best substrate
-
-
?
L-Lys-7-amido-4-methylcoumarin + H2O
L-Lys + 7-amino-4-methylcoumarin
-
best substrate
-
-
?
Leu-2-naphthylamide + H2O

Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Lys-Arg-(Met)enkephalin + H2O

Lys-Arg + (Met)enkephalin
-
-
-
-
?
Lys-Arg-(Met)enkephalin + H2O
Lys-Arg + (Met)enkephalin
-
-
-
-
?
Lys-Lys-(Met)enkephalin + H2O

Lys-Lys + (Met)enkephalin
-
-
-
-
?
Lys-Lys-(Met)enkephalin + H2O
Lys-Lys + (Met)enkephalin
-
-
-
-
?
Proteins + H2O

?
-
aminopeptidase and endopeptidase activity
-
-
?
Proteins + H2O
?
-
involved in tumor metastasis
-
-
?
Proteins + H2O
?
-
aminopeptidase and endopeptidase activity
-
-
?
Proteins + H2O
?
-
involved in processing of pre-proteins
-
-
?
Proteins + H2O
?
-
involved in human glioma, anaplastic astrocytoma, and glioblastoma progression and invasion
-
-
?
Proteins + H2O
?
-
involved in intracellular protein degradation
-
-
?
Proteins + H2O
?
-
aminopeptidase and endopeptidase activity
-
-
?
Proteins + H2O
?
-
-
-
-
?
Proteins + H2O
?
-
involved in cell growth, protein degradation, synthesis of peptide hormones and tumor metastasis
-
-
?
Proteins + H2O
?
-
involved in phagocytosis by macrophages
-
-
?
Proteins + H2O
?
-
rather broad specificity of aminopeptidase activity
-
-
?
Proteins + H2O
?
-
aminopeptidase and endopeptidase activity
-
-
?
Proteins + H2O
?
-
involved in processing of pre-proteins
-
-
?
additional information

?
-
-
activity as endopeptidase and aminopeptidase on synthetic substrates
-
-
?
additional information
?
-
-
enzyme is involved in maturation of the biologically active surfactant protein B
-
-
?
additional information
?
-
-
does not cleave benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin, benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin, and benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
?
additional information
?
-
procathepsin H is not capable of autocleavage at pH 4.5-6.5
-
-
?
additional information
?
-
-
procathepsin H is not capable of autocleavage at pH 4.5-6.5
-
-
?
additional information
?
-
-
activity as endopeptidase and aminopeptidase on synthetic substrates
-
-
?
additional information
?
-
-
influence of Pro in position P1 to P3 on rate of peptide hydrolysis, P3 i.e. 3rd amino acid in N-terminal direction relative to point of cleavage, greatest increase in activity after substrate elongation to tetrapeptide
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2E)-1,3-diphenylprop-2-en-1-one
(2E)-2-(1,3-diphenylpropylidene)hydrazinecarboxamide
-
(2E)-2-[3-(2-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(2-methoxyphenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(3-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(3-methoxyphenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(3-nitrophenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(4-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(4-methylphenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(4-nitrophenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one
(2S)-2-amino-N-[(1S)-2-(biphenyl-4-yl)-1-cyanoethyl]butanamide
-
-
(2Z)-2-(2-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, no activity remaining
(2Z)-2-(2-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, no activity remaining
(2Z)-2-(2-nitrobenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, 6.10% activity remaining
(2Z)-2-(3-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, no activity remaining
(2Z)-2-(3-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, no activity remaining
(2Z)-2-(4-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, 20.80% activity remaining
(2Z)-2-(4-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, 37.00% activity remaining
(2Z)-2-(4-nitrobenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, 25.40% activity remaining
(2Z)-2-benzylidenehydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, 14.60% activity remaining
(2Z)-2-[(2E)-1,3-diphenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC, 1 mM, 13.5% activity remaining
1,3,5-triphenyl pyrazole
-
-
1,3,5-triphenyl-2-pyrazoline
-
-
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]propan-2-ol
-
1H-spiro(cyclohexane-1,2-quinazolin)-4(3H)-one
-
competitive inhibition, 94.86% residual activity at 0.1 mM
2,5-diphenyl-1,3,4-oxadiazole
1 mM, 50.19% activity remaining
2-(2-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 25.12% activity remaining
2-(2-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 45.35% activity remaining
2-(2-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 92.07% activity remaining
2-(3-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 36.19% activity remaining
2-(3-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 48.08% activity remaining
2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 59.47% activity remaining
2-(4-(dimethylamino)phenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 88.37% residual activity at 0.1 mM
2-(4-bromophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 91.62% residual activity at 0.1 mM
2-(4-chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 98.11% residual activity at 0.1 mM
2-(4-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 30.98% activity remaining
2-(4-fluorophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 94.05% residual activity at 0.1 mM
2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 95.94% residual activity at 0.1 mM
2-(4-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 43.49% activity remaining
2-(4-methylphenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 39.18% residual activity at 0.1 mM
2-(4-methylphenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 49.89% activity remaining
2-(4-nitrophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 81.89% residual activity at 0.1 mM
2-(4-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 69.33% activity remaining
2-benzyl-N'-methyl-N'-(pyridin-3-yl)but-3-ynehydrazide
-
2-chlorobenzohydrazide
-
non-competitive inhibition; non-competitive inhibition, 89.46% residual activity at 0.01 mM
2-methoxybenzohydrazide
-
non-competitive inhibition; non-competitive inhibition, 97.83% residual activity at 0.01 mM
2-phenyl-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 79.73% residual activity at 0.1 mM
2-[[(2E)-2-(1,3-benzodioxol-5-ylmethylidene)hydrazinyl]carbonyl]-3-phenyl-1H-indole-5-sulfonamide
-
3,5-diphenyl-2-pyrazoline
-
-
3,5-diphenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
3,5-diphenyl-4-amino-1,2,4-triazole
-
non-competitive inhibition; non-competitive inhibition, 69.73% residual activity at 0.01 mM
3-(2'-hydroxy-3'-methylphenyl)-5-(2'-hydroxy-3'-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 88.11% residual activity at 0.01 mM
3-(2'-methylphenyl)-5-(2'-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 82.97% residual activity at 0.01 mM
3-(2-chlorophenyl)-1-(4-bromophenyl)prop-2-en-1-one
-
3-(2-chlorophenyl)-1-(napthalen-3-yl)prop-2-en-1-one
-
3-(2-chlorophenyl)-1-(pyridin-2-yl)prop-2-en-1-one
-
3-(2-chlorophenyl)-1-(thien-2-yl)prop-2-en-1-one
-
3-(2-hydroxy-3-methylphenyl)-5-(2-hydroxy-3-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-(2-methylphenyl)-5-(2-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-(3'-aminophenyl)-5-(3'-aminophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 16.37% residual activity at 0.01 mM
3-(3'-methylphenyl)-5-(3'-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 79.45% residual activity at 0.01 mM
3-(3'-nitrophenyl)-5-(3'-nitrophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 45.13% residual activity at 0.01 mM
3-(3-aminophenyl)-5-(3-aminophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-(3-chlorophenyl)-1-(4-aminophenyl)prop-2-en-1-one
-
3-(3-chlorophenyl)-1-(4-fluorophenyl)prop-2-en-1-one
-
3-(3-chlorophenyl)-1-(4-hydroxyphenyl)-prop-2-en-1-one
-
3-(3-chlorophenyl)-1-(furan-2-yl)prop-2-en-1-one
-
3-(3-methylphenyl)-5-(3-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-(4'-chlorophenyl)-5-(4'-chlorophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 24.35% residual activity at 0.01 mM
3-(4'-methylphenyl)-5-(4'-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 89.46% residual activity at 0.01 mM
3-(4-chlorophenyl)-1-(4-(N'-4-nitrophenyl)methylene)aminophenyl)prop-2-en-1-one
-
3-(4-chlorophenyl)-1-(4-methylphenyl)prop-2-en-1-one
-
3-(4-chlorophenyl)-1-(4-nitrophenyl)prop-2-en-1-one
-
3-(4-chlorophenyl)-5-(4-chlorophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-(4-methylphenyl)-5-(4-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-phenyl-5-(3-nitrophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-phenyl-5-(4'-nitrophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 78.11% residual activity at 0.01 mM
3-phenyl-5-(4-nitrophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
4-aminophenylmercuric acetate
-
93% inhibition at 1 mM
4-bromo-N-[(2-methylimidazo[1,2-a]pyridin-3-yl)carbonyl]benzenecarbohydrazonoyl chloride
-
4-bromochalcone phenyl hydrazone
-
-
4-chlorochalcone phenyl hydrazone
-
-
4-hydroxybenzohydrazide
-
non-competitive inhibition; non-competitive inhibition, 91.62% residual activity at 0.01 mM
4-methoxybenzohydrazide
-
non-competitive inhibition; non-competitive inhibition, 45% residual activity at 0.01 mM
4-methoxychalcone phenyl hydrazone
-
-
4-methylchalcone phenyl hydrazone
-
-
4-nitrochalcone phenyl hydrazone
-
-
5,5'-dithiobis(2-nitrobenzoic acid)
-
95% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(2-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(3-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(3-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(4-bromophenyl)-1,3-diphenyl pyrazole
-
-
5-(4-bromophenyl)-1,3-diphenyl-2-pyrazoline
-
-
5-(4-bromophenyl)-3-phenyl-2-pyrazoline
-
-
5-(4-chlorophenyl)-1,3-diphenyl pyrazole
-
-
5-(4-chlorophenyl)-1,3-diphenyl-2-pyrazoline
-
-
5-(4-chlorophenyl)-3-phenyl-2-pyrazoline
-
-
5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(4-methoxyphenyl)-1,3-diphenyl pyrazole
-
-
5-(4-methoxyphenyl)-1,3-diphenyl-2-pyrazoline
-
-
5-(4-methoxyphenyl)-3-phenyl-2-pyrazoline
-
-
5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(4-methylphenyl)-1,3-diphenyl pyrazole
-
-
5-(4-methylphenyl)-1,3-diphenyl-2-pyrazoline
-
-
5-(4-methylphenyl)-3-phenyl-2-pyrazoline
-
-
5-(4-methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(4-nitrophenyl)-1,3-diphenyl pyrazole
-
-
5-(4-nitrophenyl)-1,3-diphenyl-2-pyrazoline
-
-
5-(4-nitrophenyl)-3-phenyl-2-pyrazoline
-
-
5-(4-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
acetyl-(Ala)2-Pro-Ala-CH2Cl
-
100% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
acetyl-(Ala)2-Pro-Val-CH2Cl
-
100% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
acetyl-(Ala)4-CH2Cl
-
100% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
alpha-2-Macroglobulin
-
-
-
benzyloxycarbonyl-Gly-Leu-NH
-
inhibits processing of proenzyme to active form
Benzyloxycarbonyl-Leu-NH2
-
inhibits formation of active enzyme from procathepsin H
Benzyloxycarbonyl-Phe-Phe-CHN2
-
31% inhibition at 0.01 mM
bestatin
-
62% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
CdCl2
-
90% inhibition at 1 mM
chalcone phenyl hydrazone
-
-
chicken egg white cystatin
-
-
-
chymostatin B
-
47% inhibition at 0.016 mM
-
CNWAAGYNCGGGS-NH2
-
cyclic peptide with intramolecular disulfide bond, comparison of inhibitory effect with cathepsin K, cathepsin L, cathepsin B and papain
CNWTLGGYKCGGGS-NH2
-
cyclic peptide with intramolecular disulfide bond, comparison of inhibitory effect with cathepsin K, cathepsin L, cathepsin B and papain
CoCl2
-
100% inhibition at 1 mM
CPI-H
-
peptide inhibitor of 13 kDa from rabbit skeletal muscle, noncompetitive
-
CPI-L
-
peptide inhibitor of 23 kDa from rabbit skeletal muscle, noncompetitive
-
CuCl2
-
94% inhibition at 1 mM
CWEWGGWHCGGSS-OH
-
cyclic peptide with intramolecular disulfide bond, comparison of inhibitory effect with cathepsin K, cathepsin L, cathepsin B and papain
CWSMMGFQCGGGS-NH2
-
cyclic peptide with intramolecular disulfide bond, comparison of inhibitory effect with cathepsin K, cathepsin L, cathepsin B and papain
cystatin C, full-length
-
-
-
cystatin C, truncated form
-
deletion of 10 N-terminal amino acids
-
decyl bromide
-
100% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
DTNB
-
100% inhibition at 1 mM
E-64
-
irreversible active site inhibitor
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
Human cystatin C
-
Ki: 0.01-0.03 nM
-
Hyamine 1622
-
52% inhibition at 1 mM
Leu-CH2-Cl
-
complete inhibition at 0.01 mM
MnSO4
-
64% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
N'-(4-[(E)-[2-(2-formylphenyl)hydrazinylidene]methyl]phenyl)-N-phenylimidoformamide
-
N-(3-methoxypyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
-
N-acetyl-3,5-diphenyl pyrazolines
-
-
N-acetyl-5-(4-bromophenyl)-3-phenyl-2-pyrazoline
-
-
N-acetyl-5-(4-chlorophenyl)-3-phenyl-2-pyrazoline
-
-
N-acetyl-5-(4-methoxyphenyl)-3-phenyl-2-pyrazoline
-
-
N-acetyl-5-(4-methylphenyl)-3-phenyl-2-pyrazoline
-
-
N-acetyl-5-(4-nitrophenyl)-3-phenyl-2-pyrazoline
-
-
N-benzoyl-3,5-diphenylpyrazoline
-
66.19% residual activity at 0.01 mM
N-benzoyl-5-(2-chloro phenyl)-3-phenylpyrazoline
-
-
N-benzoyl-5-(2-chlorophenyl)-3-phenylpyrazoline
-
55.13% residual activity at 0.01 mM
N-benzoyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
-
79.37% residual activity at 0.01 mM
N-benzoyl-5-(2-nitrophenyl)-3-phenylpyrazoline
-
34.77% residual activity at 0.01 mM
N-benzoyl-5-(3-chloro phenyl)-3-phenylpyrazoline
-
-
N-benzoyl-5-(3-chlorophenyl)-3-phenylpyrazoline
-
44.2% residual activity at 0.01 mM
N-benzoyl-5-(3-methoxy phenyl)-3-phenylpyrazoline
-
-
N-benzoyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
-
76.06% residual activity at 0.01 mM
N-benzoyl-5-(3-nitrophenyl)-3-phenylpyrazoline
-
27.49% residual activity at 0.01 mM
N-benzoyl-5-(4-chloro phenyl)-3-phenylpyrazoline
-
-
N-benzoyl-5-(4-chlorophenyl)-3-phenylpyrazoline
-
62.47% residual activity at 0.01 mM
N-benzoyl-5-(4-methoxy phenyl)-3-phenylpyrazoline
-
-
N-benzoyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
-
69.69% residual activity at 0.01 mM
N-benzoyl-5-(4-nitrophenyl)-3-phenylpyrazoline
-
28.77% residual activity at 0.01 mM
N-benzyl-5-hydroxy-1-methyl-2-[2-[(1,3,4-oxadiazol-2-ylcarbonyl)amino]propan-2-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide
-
N-formyl-3,5-diphenylpyrazoline
-
76.78% residual activity at 10 mM
N-formyl-5-(2-chlorophenyl)-3-phenylpyrazoline
-
61.38% residual activity at 10 mM
N-formyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
-
92.97% residual activity at 0.001 mM
N-formyl-5-(2-nitrophenyl)-3-phenylpyrazoline
-
30.2% residual activity at 0.001 mM
N-formyl-5-(3-chlorophenyl)-3-phenylpyrazoline
-
49.57% residual activity at 0.001 mM
N-formyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
-
86.03% residual activity at 0.001 mM
N-formyl-5-(3-nitrophenyl)-3-phenylpyrazoline
-
14.15% residual activity at 0.001 mM
N-formyl-5-(4-chlorophenyl)-3-phenylpyrazoline
-
69.38% residual activity at 0.001 mM
N-formyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
-
80.06% residual activity at 0.001 mM
N-formyl-5-(4-nitrophenyl)-3-phenylpyrazoline
-
27.64% residual activity at 0.001 mM
N-[(1E,2S)-1-(2-benzoylhydrazinylidene)-4-phenylbutan-2-yl]-N2-(piperidin-1-ylcarbonyl)-L-leucinamide
-
N-[(1E,3S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl]-L-norvalinamide
-
-
N-[(5S,8S,11S,13Z,19S)-8-(4-fluorobenzyl)-5-formyl-2,7,10-trioxo-18-oxa-1,6,9-triazabicyclo[17.2.1]docos-13-en-11-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
N-[(E)-(phenylimino)methyl]benzamide
1 mM, 69.90% activity remaining
N-[(E)-[(2-chlorophenyl)imino]methyl]benzamide
1 mM, 25.66% activity remaining
N-[(E)-[(2-methoxyphenyl)imino]methyl]benzamide
1 mM, 41.11% activity remaining
N-[(E)-[(2-nitrophenyl)imino]methyl]benzamide
1 mM, 90.07% activity remaining
N-[(E)-[(3-chlorophenyl)imino]methyl]benzamide
1 mM, 39.45% activity remaining
N-[(E)-[(3-methoxyphenyl)imino]methyl]benzamide
1 mM, 49.59% activity remaining
N-[(E)-[(3-nitrophenyl)imino]methyl]benzamide
1 mM, 73.01% activity remaining
N-[(E)-[(4-chlorophenyl)imino]methyl]benzamide
1 mM, 24.75% activity remaining
N-[(E)-[(4-methoxyphenyl)imino]methyl]benzamide
1 mM, 40.2% activity remaining
N-[(E)-[(4-methylphenyl)imino]methyl]benzamide
1 mM, 39.93% activity remaining
N-[(E)-[(4-nitrophenyl)imino]methyl]benzamide
1 mM, 75.07% activity remaining
N-[2-(4-methoxyphenyl)ethyl]-2-(2-phenoxyphenyl)acetamide
-
N2-(morpholin-4-ylcarbonyl)-N-[(1E,3S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl]-L-leucinamide
-
-
p-Hydroxymercuriphenylsulfonic acid
-
83% inhibition at 0.011 mM, substrate Leu-2-N-naphthylamine
PCMB
-
46% inhibition at 1 mM
phenylacetyl hydrazine
-
non-competitive inhibition; non-competitive inhibition, 81.08% residual activity at 0.01 mM
Soybean trypsin inhibitor
-
Thiol proteinase inhibitor
-
Zn(CH3COO)2
-
85% inhibition at 1 mM
ZnSO4
-
87% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
(2E)-1,3-diphenylprop-2-en-1-one

-
(2E)-1,3-diphenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 93.50% activity remaining
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one

-
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 42.00% activity remaining
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one

-
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 66.00% activity remaining
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one

-
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 0.30% activity remaining
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one

-
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 51.40% activity remaining
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one

-
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 55.20% activity remaining
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one

-
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 73.30% activity remaining
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one

-
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 55.60% activity remaining
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one

-
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 92.50% activity remaining
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one

-
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 61.80% activity remaining
1,10-phenanthroline

-
4% inhibition at 5 mM
1,10-phenanthroline
-
inhibits processing of proenzyme to active form
2,2'-dipyridyl disulfide

-
thiol-specific two-protonic-state reactivity probe
2,2'-dipyridyl disulfide
-
96% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
antipain

-
53% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
antipain
-
91% inhibition at 0.1 mM
antipain
-
at 0.1 mM, 95% inhibition
chicken cystatin

-
Ki: 0.1 nM
-
cystatin

-
-
-
cystatin C

-
-
-
cystatin C
physiological inhibitor of cathepsin H
-
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate

-
90% inhibition at 0.001 mM, substrate Leu-2-N-naphthylamine
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
100% inhibition at 0.1 mM
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
E-64-d, inhibits processing of proenzyme to synthetic analogs
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
-
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
E-64-d, inhibits processing of proenzyme to active form
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
65-76% inhibition at 0.01 mg/ml, isoform-dependent
HgCl2

-
100% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
HgCl2
-
73% inhibition at 1 mM
human stefin A

-
Ki: 0.1-0.16 nM
-
human stefin B

-
Ki: 0.003 nM
-
iodoacetamide

-
91% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
iodoacetamide
-
99% inhibition at 1 mM
iodoacetic acid

-
100% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
iodoacetic acid
-
99% inhibition at 1 mM
iodoacetic acid
-
at 1 mM, 99% inhibition
iodoacetic acid
-
71-77% inhibition at 0.5 mM, isoenzyme-dependent
Leu-CH2Cl

-
92% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
Leu-CH2Cl
-
85% inhibition at 0.001 mM
leupeptin

-
100% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
leupeptin
-
complete inhibition at 0.01 mM
leupeptin
-
80% inhibition at 0.1 mM
leupeptin
-
low sensitivity
leupeptin
-
29% inhibition at 0.021 mM
leupeptin
-
at 0.1 mM, 99% inhibition
leupeptin
-
Ki: 0.005 mM; low sensitivity
leupeptin
-
inhibits processing of proenzyme to active form
N-ethylmaleimide

-
98% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
N-ethylmaleimide
-
69% inhibition at 1 mM
Proteinase inhibitor

-
rat liver
-
Proteinase inhibitor
-
from rabbit lung
-
puromycin

-
20% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
puromycin
-
36% inhibition at 1 mM
Soybean trypsin inhibitor

-
8% inhibition at 0.005 mM
-
Soybean trypsin inhibitor
-
non-specific
-
Thiol proteinase inhibitor

-
from human serum, human lung, molecular weights: 13000 and 80000, the latter including haptoglobin, 4-7% inhibition
-
Thiol proteinase inhibitor
-
proteinase inhibitor from rat, man, hog, Tetrahymena, tuna, chicken, toad, purified rat lung inhibitors have molecular weight of 14000, purified hog kidney inhibitors have molecular weight of 11000, also high molecular weight inhibitors in human and rat serum, tissue distributions in humans and rat: inhibitors widely distributed, probaly regulatory function
-
Thiol proteinase inhibitor
-
proteinase inhibitor from rat, man, hog, Tetrahymena, tuna, chicken, toad, purified rat lung inhibitors have molecular weight of 14000, purified hog kidney inhibitors have molecular weight of 11000, also high molecular weight inhibitors in human and rat serum, tissue distributions in humans and rat: inhibitors widely distributed, probaly regulatory function
-
Thiol proteinase inhibitor
-
proteinase inhibitor from rat, man, hog, Tetrahymena, tuna, chicken, toad, purified rat lung inhibitors have molecular weight of 14000, purified hog kidney inhibitors have molecular weight of 11000, also high molecular weight inhibitors in human and rat serum, tissue distributions in humans and rat: inhibitors widely distributed, probaly regulatory function
-
Thiol proteinase inhibitor
-
proteinase inhibitor from rat, man, hog, Tetrahymena, tuna, chicken, toad, purified rat lung inhibitors have molecular weight of 14000, purified hog kidney inhibitors have molecular weight of 11000, also high molecular weight inhibitors in human and rat serum, tissue distributions in humans and rat: inhibitors widely distributed, probaly regulatory function
-
Thiol proteinase inhibitor
-
proteinase inhibitor from rat, man, hog, Tetrahymena, tuna, chicken, toad, purified rat lung inhibitors have molecular weight of 14000, purified hog kidney inhibitors have molecular weight of 11000, also high molecular weight inhibitors in human and rat serum, tissue distributions in humans and rat: inhibitors widely distributed, probaly regulatory function
-
thiol-blocking agents

-
-
thiol-blocking agents
-
-
thiol-blocking agents
-
-
tosyl-Leu-CH2Cl

-
63% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
tosyl-Leu-CH2Cl
-
89% inhibition at 1 mM
tosyl-Leu-CH2Cl
-
60% inhibition at 0.01 mM
tosyl-Leu-CH2Cl
-
17-35% inhibition at 0.1 mM, isoenzyme-dependent
tosyl-Phe-CH2Cl

-
69% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
tosyl-Phe-CH2Cl
-
84%inhibition at 1 mM
tosyl-Phe-CH2Cl
-
79% inhibition at 0.01 mM
additional information

-
amastatin, arphamenine A, and bestatin have no effect on cathepsin H
-
additional information
2,5-diaryloxadiazoles and their precursors as inhibitors of cathepsins B, H and L, synthesis and inhibitory potencies, pharmacological evaluation, molecular docking, overview. Structure-activity relationship studies show that 2,5-diaryloxadiazoles are less inhibitory than their precursors, N-subsituted benzylidenebenzohydrazides. Cathepsin H activity is maximally inhibited by (2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one and (2Z)-2-[(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide, assay with liver hommogenate. All compounds exhibited a competitive type of inhibition
-
additional information
chalcones, semicarbazones and pyrazolines as inhibitors of cathepsins H, synthesis and inhibitory potencies, pharmacological evaluation, molecular docking, overview. Structure-activity relationship analysis
-
additional information
semicarbazones and thiosemicarbazones as inhibitors of cathepsins H, active site docking study and structure-activity relationship analysis, comparison to cathepsin L, overview
-
additional information
synthesis of a small library of chalcones and study of their role as inhibitors of cathepsins, overview. The most potent inhibitors among all compounds are chloro-substituted compounds for cathepsin H. Docking analysis and modeling, overview
-
additional information
no significant inhibitory effect of enzyme propeptide fragments, detailed analysis using several different peptides. Recombinant enzyme lacking the mini-chain shows inhibitory interaction
-
additional information
molecular basis for the inhibition of the mature enzyme by the prodomain. The prodomain of procathepsin H has an N-terminal helical subdomain (Ala1P-Ser75P) and an extended portion (Glu76P-Pro93P) that links the helical subdomain to Tyr1 of the mature domain
-
additional information
-
molecular basis for the inhibition of the mature enzyme by the prodomain. The prodomain of procathepsin H has an N-terminal helical subdomain (Ala1P-Ser75P) and an extended portion (Glu76P-Pro93P) that links the helical subdomain to Tyr1 of the mature domain
-
additional information
-
amastatin, arphamenine A, and bestatin have no effect on cathepsin H
-
additional information
-
not inhibitory: pepstatin, bestatin, puromycin, phenylmethylsulfonylfluoride, trypsin inhibitor
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Altered expression of genes involved in the production and degradation of endometrial extracellular matrix in patients with unexplained infertility and recurrent miscarriages.
Alveolitis, Extrinsic Allergic
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Alzheimer Disease
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Arthritis
Determination of cathepsins B and H in sera and synovial fluids of patients with different joint diseases.
Arthritis, Rheumatoid
Determination of cathepsins B and H in sera and synovial fluids of patients with different joint diseases.
Astrocytoma
Expression and the role of cathepsin H in human glioma progression and invasion.
Atherosclerosis
Enzymatically modified LDL induces cathepsin H in human monocytes: potential relevance in early atherogenesis.
Brain Neoplasms
Some physicochemical properties of cathepsin H from human meningioma.
Brain Neoplasms
[Cathepsin H activity in the human brain and human brain neoplasms]
Breast Neoplasms
Cathepsins B, H and L in human breast carcinoma.
Carcinogenesis
Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.
Carcinogenesis
[Changes in active cysteine cathepsins in lysosomes from tissues thyroid papillary carcinomas with various biological characteristics].
Carcinoma
Alterations in cathepsin H activity and protein patterns in human colorectal carcinomas.
Carcinoma
Analysis of a truncated form of cathepsin H in human prostate tumor cells.
Carcinoma
Cathepsin H expression distinguishes oncocytomas from renal cell carcinomas.
Carcinoma
Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma.
Carcinoma, Hepatocellular
Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells.
Carcinoma, Papillary
[Changes in active cysteine cathepsins in lysosomes from tissues thyroid papillary carcinomas with various biological characteristics].
Carcinoma, Renal Cell
Cathepsin H expression distinguishes oncocytomas from renal cell carcinomas.
Carcinosarcoma
Molecular cloning of rat precursor cathepsin H and the expression of five lysosomal cathepsins in normal tissues and in a rat carcinosarcoma.
cathepsin h deficiency
Cathepsin H deficiency decreases hypoxia-ischemia-induced hippocampal atrophy in neonatal mice through attenuated TLR3/IFN-? signaling.
cathepsin h deficiency
Cathepsin H deficiency in mice induces excess Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade.
Cholesteatoma
Gene expression analysis of human middle ear cholesteatoma using complementary DNA arrays.
Colorectal Neoplasms
Alterations in cathepsin H activity and protein patterns in human colorectal carcinomas.
Colorectal Neoplasms
Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer.
Cryptogenic Organizing Pneumonia
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Diabetes Mellitus, Type 1
Genetic and environmental factors regulate the type 1 diabetes gene CTSH via differential DNA methylation.
Encephalomyelitis
Cathepsin H deficiency in mice induces excess Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade.
Encephalomyelitis, Autoimmune, Experimental
Cathepsin H deficiency in mice induces excess Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade.
Epstein-Barr Virus Infections
Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors.
Gallbladder Neoplasms
Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics.
Glioblastoma
Expression and the role of cathepsin H in human glioma progression and invasion.
Glioma
Expression and the role of cathepsin H in human glioma progression and invasion.
Huntington Disease
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Idiopathic Pulmonary Fibrosis
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Infections
Channel catfish, Ictalurus punctatus, cysteine proteinases: cloning, characterisation and expression of cathepsin H and L.
Infections
Diagnosis of Fasciola gigantica infection using a monoclonal antibody-based sandwich ELISA for detection of circulating cathepsin B3 protease.
Infections
The combined recombinant cathepsin L1H and cathepsin B3 vaccine against Fasciola gigantica infection.
Infections
Vaccine potential of recombinant cathepsin B against Fasciola gigantica.
Infertility
Altered expression of genes involved in the production and degradation of endometrial extracellular matrix in patients with unexplained infertility and recurrent miscarriages.
Inflammatory Breast Neoplasms
Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer.
Insulinoma
Immunocytochemical localization of cathepsins B and H in human pancreatic endocrine cells and insulinoma cells.
Lung Neoplasms
Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking.
Lung Neoplasms
[Serum activity of chitotriosidase, lysozyme and cathepsin H in patients with lung cancer and patients with inflammatory exudate (preliminary report)]
Melanoma
Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients.
Melanoma
Enzyme-linked immunosorbent assay for the detection of total cathepsin H in human tissue cytosols and sera.
Melanoma
Generation of a double binary transgenic zebrafish model to study myeloid gene regulation in response to oncogene activation in melanocytes.
Melanoma, Amelanotic
Cathepsin B-like activity in viable tumor cells isolated from rodent tumors.
Melanoma, Experimental
Cathepsin B: association with plasma membrane in metastatic tumors.
Meningioma
Some physicochemical properties of cathepsin H from human meningioma.
Mouth Neoplasms
[Activity of cathepsin H in blood and biopsies of patients with precancerous conditions and mouth cancer]
Multiple Sclerosis
Cathepsin H deficiency in mice induces excess Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade.
Narcolepsy
Genetic association, seasonal infections and autoimmune basis of narcolepsy.
Narcolepsy
ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy.
Narcolepsy
The autoimmune basis of narcolepsy.
Neoplasm Metastasis
Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients.
Neoplasms
Alterations in cathepsin H activity and protein patterns in human colorectal carcinomas.
Neoplasms
Analysis of a truncated form of cathepsin H in human prostate tumor cells.
Neoplasms
Cathepsin B activity in human lung tumor cell lines: ultrastructural localization, pH sensitivity, and inhibitor status at the cellular level.
Neoplasms
Cathepsin B-like activity in viable tumor cells isolated from rodent tumors.
Neoplasms
Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.
Neoplasms
Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells.
Neoplasms
Cathepsins B, H and L in human breast carcinoma.
Neoplasms
Cathepsins in basal cell carcinomas: activity, immunoreactivity and mRNA staining of cathepsins B, D, H and L.
Neoplasms
Cysteine proteases and cell differentiation: excystment of the ciliated protist Sterkiella histriomuscorum.
Neoplasms
Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking.
Neoplasms
Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer.
Neoplasms
Design, synthesis and docking studies of bischalcones based quinazoline-2(1H)-ones and quinazoline-2(1H)-thiones derivatives as novel inhibitors of cathepsin B and cathepsin H.
Neoplasms
Expression and the role of cathepsin H in human glioma progression and invasion.
Neoplasms
IFN-gamma increases cathepsin H mRNA levels in mouse macrophages.
Neoplasms
ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy.
Neoplasms
Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse.
Neoplasms
Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer.
Neoplasms
Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma.
Neoplasms
Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer.
Neoplasms
Some physicochemical properties of cathepsin H from human meningioma.
Neoplasms
The role of peptidases in cancer of the rectum and sigmoid colon.
Neoplasms
Use of a transgenic mouse model to identify markers of human lung tumors.
Neoplasms
[Activity of cathepsin H in blood and biopsies of patients with precancerous conditions and mouth cancer]
Neoplasms
[Cathepsin H activity in the human brain and human brain neoplasms]
Neoplasms
[Changes in active cysteine cathepsins in lysosomes from tissues thyroid papillary carcinomas with various biological characteristics].
Neoplasms
[Cysteine cathepsins secreted into the blood as markers of tumor growth]
Osteoradionecrosis
[Cysteine cathepsins secreted into the blood as markers of tumor growth]
Osteosarcoma
Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.
Pancreatic Neoplasms
Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization.
Pneumonia
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Polycystic Kidney, Autosomal Dominant
Functional defects in lysosomal enzymes in autosomal dominant polycystic kidney disease (ADPKD): abnormalities in synthesis, molecular processing, polarity, and secretion.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases.
Precancerous Conditions
[Activity of cathepsin H in blood and biopsies of patients with precancerous conditions and mouth cancer]
Prostatic Intraepithelial Neoplasia
Analysis of a truncated form of cathepsin H in human prostate tumor cells.
Prostatic Neoplasms
Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.
Prostatic Neoplasms
Cathepsin H mediates the processing of talin and regulates migration of prostate cancer cells.
Pulmonary Alveolar Proteinosis
Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis.
Pulmonary Eosinophilia
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Thymoma
A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis.
Thyroid Neoplasms
Favorable Prognostic Impact of Cathepsin H (CTSH) High Expression in Thyroid Carcinoma.
Tuberculosis
Investigating potential transmission of antimicrobial resistance in an open-plan hospital ward: a cross-sectional metagenomic study of resistome dispersion in a lower middle-income setting.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.263 - 8.19
(2E)-1,3-diphenylprop-2-en-1-one
0.066
(2E)-2-(1,3-diphenylpropylidene)hydrazinecarboxamide
pH 6.0, 37ưC
0.033
(2E)-2-[3-(2-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.054
(2E)-2-[3-(2-methoxyphenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.06
(2E)-2-[3-(3-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.066
(2E)-2-[3-(3-methoxyphenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.033
(2E)-2-[3-(3-nitrophenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.021
(2E)-2-[3-(4-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.04
(2E)-2-[3-(4-methylphenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.032
(2E)-2-[3-(4-nitrophenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.11 - 0.43
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
0.1 - 1.08
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one
0.027 - 0.312
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one
0.11 - 0.63
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one
0.06 - 0.7
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one
0.083 - 1.66
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
0.138 - 0.71
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
0.151 - 7.04
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one
0.1 - 1
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one
0.0037
(2S)-2-amino-N-[(1S)-2-(biphenyl-4-yl)-1-cyanoethyl]butanamide
-
-
0.208
(2Z)-2-(2-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, no activity remaining
0.28
(2Z)-2-(2-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, no activity remaining
0.009
(2Z)-2-(2-nitrobenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, 6.10% activity remaining
0.704
(2Z)-2-(3-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, no activity remaining
0.016
(2Z)-2-(3-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, no activity remaining
0.17
(2Z)-2-(4-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, 20.80% activity remaining
0.35
(2Z)-2-(4-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, 37.00% activity remaining
0.2
(2Z)-2-(4-nitrobenzylidene)hydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, 25.40% activity remaining
0.06
(2Z)-2-benzylidenehydrazinecarbothioamide
pH 6.0, 37ưC, 1 mM, 14.60% activity remaining
0.1
(2Z)-2-[(2E)-1,3-diphenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.043
(2Z)-2-[(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.066
(2Z)-2-[(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.096
(2Z)-2-[(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.074
(2Z)-2-[(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.023
(2Z)-2-[(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.029
(2Z)-2-[(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.054
(2Z)-2-[(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.045
(2Z)-2-[(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC
0.025
(2Z)-2-[(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37ưC, 1 mM, 13.50% activity remaining
0.01859
1,3,5-triphenyl pyrazole
-
pH 7, 37ưC
0.005388
1,3,5-triphenyl-2-pyrazoline
-
pH 7, 37ưC
0.09009
1H-spiro(cyclohexane-1,2-quinazolin)-4(3H)-one
-
at pH 7.0 and 37ưC
0.00272
2,5-diphenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.00056
2-(2-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.00147
2-(2-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.00669
2-(2-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.00113
2-(3-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.00161
2-(3-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.00385
2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.01858
2-(4-(dimethylamino)phenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37ưC
0.05263
2-(4-bromophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37ưC
0.02325
2-(4-chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37ưC
0.001
2-(4-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.00818
2-(4-fluorophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37ưC
0.05682
2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37ưC
0.00133
2-(4-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.0025
2-(4-methylphenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37ưC
0.00255
2-(4-methylphenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.01042
2-(4-nitrophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37ưC
0.00496
2-(4-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37ưC
0.0901
2-chlorobenzohydrazide
0.588
2-methoxybenzohydrazide
0.01441
2-phenyl-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37ưC
0.006024
3,5-diphenyl-2-pyrazoline
-
pH 7, 37ưC
0.192
3,5-diphenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37ưC
0.0232
3,5-diphenyl-4-amino-1,2,4-triazole
0.0781
3-(2'-hydroxy-3'-methylphenyl)-5-(2'-hydroxy-3'-methylphenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37ưC
0.0532
3-(2'-methylphenyl)-5-(2'-methylphenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37ưC
0.0214
3-(2-chlorophenyl)-1-(4-bromophenyl)prop-2-en-1-one
pH 5.0, 37ưC
0.0989
3-(2-chlorophenyl)-1-(napthalen-3-yl)prop-2-en-1-one
pH 5.0, 37ưC
0.0472
3-(2-chlorophenyl)-1-(pyridin-2-yl)prop-2-en-1-one
pH 5.0, 37ưC
0.217
3-(2-chlorophenyl)-1-(thien-2-yl)prop-2-en-1-one
pH 5.0, 37ưC
0.0781
3-(2-hydroxy-3-methylphenyl)-5-(2-hydroxy-3-methylphenyl)-4-amino-1,2,4-triazole
-
pH 5, 37ưC
0.0532
3-(2-methylphenyl)-5-(2-methylphenyl)-4-amino-1,2,4-triazole
-
pH 5, 37ưC
0.002
3-(3'-aminophenyl)-5-(3'-aminophenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37ưC
0.0387
3-(3'-methylphenyl)-5-(3'-methylphenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37ưC
0.0086
3-(3'-nitrophenyl)-5-(3'-nitrophenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37ưC
0.002
3-(3-aminophenyl)-5-(3-aminophenyl)-4-amino-1,2,4-triazole
-
pH 5, 37ưC
0.128
3-(3-chlorophenyl)-1-(4-aminophenyl)prop-2-en-1-one
pH 5.0, 37ưC
0.0317
3-(3-chlorophenyl)-1-(4-fluorophenyl)prop-2-en-1-one
pH 5.0, 37ưC
0.163
3-(3-chlorophenyl)-1-(4-hydroxyphenyl)-prop-2-en-1-one
pH 5.0, 37ưC
0.298
3-(3-chlorophenyl)-1-(furan-2-yl)prop-2-en-1-one
pH 5.0, 37ưC
0.0387
3-(3-methylphenyl)-5-(3-methylphenyl)-4-amino-1,2,4-triazole
-
pH 5, 37ưC
0.0033
3-(4'-chlorophenyl)-5-(4'-chlorophenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37ưC
0.0901
3-(4'-methylphenyl)-5-(4'-methylphenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37ưC
0.0133
3-(4-chlorophenyl)-1-(4-(N'-4-nitrophenyl)methylene)aminophenyl)prop-2-en-1-one
pH 5.0, 37ưC
0.0416
3-(4-chlorophenyl)-1-(4-methylphenyl)prop-2-en-1-one
pH 5.0, 37ưC
0.405
3-(4-chlorophenyl)-1-(4-nitrophenyl)prop-2-en-1-one
pH 5.0, 37ưC
0.0033
3-(4-chlorophenyl)-5-(4-chlorophenyl)-4-amino-1,2,4-triazole
-
pH 5, 37ưC
0.0901
3-(4-methylphenyl)-5-(4-methylphenyl)-4-amino-1,2,4-triazole
-
pH 5, 37ưC
0.0086
3-phenyl-5-(3-nitrophenyl)-4-amino-1,2,4-triazole
-
pH 5, 37ưC
0.0364
3-phenyl-5-(4'-nitrophenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37ưC
0.0364
3-phenyl-5-(4-nitrophenyl)-4-amino-1,2,4-triazole
-
pH 5, 37ưC
0.0026
4-bromochalcone phenyl hydrazone
-
pH 7, 37ưC
0.0011
4-chlorochalcone phenyl hydrazone
-
pH 7, 37ưC
0.1123
4-hydroxybenzohydrazide
0.0082
4-methoxybenzohydrazide
0.001695
4-methoxychalcone phenyl hydrazone
-
pH 7, 37ưC
0.0029
4-methylchalcone phenyl hydrazone
-
pH 7, 37ưC
0.001905
4-nitrochalcone phenyl hydrazone
-
pH 7, 37ưC
0.06
5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37ưC
0.04
5-(2-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37ưC
0.025
5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37ưC
0.043
5-(3-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37ưC
0.038
5-(3-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37ưC
0.0038
5-(4-bromophenyl)-1,3-diphenyl pyrazole
-
pH 7, 37ưC
0.002907
5-(4-bromophenyl)-1,3-diphenyl-2-pyrazoline
-
pH 7, 37ưC
0.00537
5-(4-bromophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37ưC
0.002346
5-(4-chlorophenyl)-1,3-diphenyl pyrazole
-
pH 7, 37ưC
0.001174
5-(4-chlorophenyl)-1,3-diphenyl-2-pyrazoline
-
pH 7, 37ưC
0.001568
5-(4-chlorophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37ưC
0.066
5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37ưC
0.0033
5-(4-methoxyphenyl)-1,3-diphenyl pyrazole
-
pH 7, 37ưC
0.002119
5-(4-methoxyphenyl)-1,3-diphenyl-2-pyrazoline
-
pH 7, 37ưC
0.0098
5-(4-methoxyphenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37ưC
0.048
5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37ưC
0.007396
5-(4-methylphenyl)-1,3-diphenyl pyrazole
-
pH 7, 37ưC
0.004184
5-(4-methylphenyl)-1,3-diphenyl-2-pyrazoline
-
pH 7, 37ưC
0.0082
5-(4-methylphenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37ưC
0.048
5-(4-methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37ưC
0.00257
5-(4-nitrophenyl)-1,3-diphenyl pyrazole
-
pH 7, 37ưC
0.003158
5-(4-nitrophenyl)-1,3-diphenyl-2-pyrazoline
-
pH 7, 37ưC
0.0033
5-(4-nitrophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37ưC
0.06
5-(4-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37ưC
0.00000052
bovine stefin B
-
pH 6.5, 25ưC, native enzyme
-
0.0048
chalcone phenyl hydrazone
-
pH 7, 37ưC
0.000000049
chicken cystatin
-
pH 6.5, 25ưC, mutant lacking the mini chain
-
0.000000095 - 0.00000053
chicken egg white cystatin
-
0.0179
CNWAAGYNCGGGS-NH2
-
pH 6.8, 22ưC
0.0051
CNWTLGGYKCGGGS-NH2
-
pH 6.8, 22ưC
0.00000033
CPI-H
-
pH 6.2, 30ưC
-
0.0000005
CPI-L
-
pH 6.2, 30ưC
-
0.0049
CWEWGGWHCGGSS-OH
-
pH 6.8, 22ưC
0.0039
CWSMMGFQCGGGS-NH2
-
pH 6.8, 22ưC
0.000000071
cystatin C, full-length
-
25ưC, pH 7.0
-
0.00000032
cystatin C, truncated form
-
25ưC, pH 7.0
-
0.000000099
human stefin A
-
pH 6.5, 25ưC, mutant lacking the mini chain
-
0.000000074
human stefin B
-
pH 6.5, 25ưC, mutant lacking the mini chain
-
0.01767
N-acetyl-3,5-diphenyl pyrazolines
-
pH 7, 37ưC
0.01266
N-acetyl-5-(4-bromophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37ưC
0.01
N-acetyl-5-(4-chlorophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37ưC
0.14
N-acetyl-5-(4-methoxyphenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37ưC
0.03546
N-acetyl-5-(4-methylphenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37ưC
0.02432
N-acetyl-5-(4-nitrophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37ưC
0.0032
N-benzoyl-3,5-diphenylpyrazoline
0.00189
N-benzoyl-5-(2-chloro phenyl)-3-phenylpyrazoline
-
pH 7, 37ưC
0.00189
N-benzoyl-5-(2-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.00965
N-benzoyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
0.00144
N-benzoyl-5-(2-nitrophenyl)-3-phenylpyrazoline
0.00181
N-benzoyl-5-(3-chloro phenyl)-3-phenylpyrazoline
-
pH 7, 37ưC
0.00181
N-benzoyl-5-(3-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.00503
N-benzoyl-5-(3-methoxy phenyl)-3-phenylpyrazoline
-
pH 7, 37ưC
0.00503
N-benzoyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.00098
N-benzoyl-5-(3-nitrophenyl)-3-phenylpyrazoline
0.00301
N-benzoyl-5-(4-chloro phenyl)-3-phenylpyrazoline
-
pH 7, 37ưC
0.00301
N-benzoyl-5-(4-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.0041
N-benzoyl-5-(4-methoxy phenyl)-3-phenylpyrazoline
-
pH 7, 37ưC
0.0041
N-benzoyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.00127
N-benzoyl-5-(4-nitrophenyl)-3-phenylpyrazoline
0.000174
N-formyl-3,5-diphenylpyrazoline
0.000135
N-formyl-5-(2-chlorophenyl)-3-phenylpyrazoline
0.000387
N-formyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
0.0000963
N-formyl-5-(2-nitrophenyl)-3-phenylpyrazoline
0.00013
N-formyl-5-(3-chlorophenyl)-3-phenylpyrazoline
0.000272
N-formyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
0.0000519
N-formyl-5-(3-nitrophenyl)-3-phenylpyrazoline
0.000137
N-formyl-5-(4-chlorophenyl)-3-phenylpyrazoline
0.000221
N-formyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
0.000058
N-formyl-5-(4-nitrophenyl)-3-phenylpyrazoline
0.00014
N-[(1E,3S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl]-L-norvalinamide
-
-
0.00214
N-[(E)-(phenylimino)methyl]benzamide
pH 5.0, 37ưC
0.00068
N-[(E)-[(2-chlorophenyl)imino]methyl]benzamide
pH 5.0, 37ưC
0.0014
N-[(E)-[(2-methoxyphenyl)imino]methyl]benzamide
pH 5.0, 37ưC
0.00484
N-[(E)-[(2-nitrophenyl)imino]methyl]benzamide
pH 5.0, 37ưC
0.00113
N-[(E)-[(3-chlorophenyl)imino]methyl]benzamide
pH 5.0, 37ưC
0.00168
N-[(E)-[(3-methoxyphenyl)imino]methyl]benzamide
pH 5.0, 37ưC
0.00364
N-[(E)-[(3-nitrophenyl)imino]methyl]benzamide
pH 5.0, 37ưC
0.00044
N-[(E)-[(4-chlorophenyl)imino]methyl]benzamide
pH 5.0, 37ưC
0.00133
N-[(E)-[(4-methoxyphenyl)imino]methyl]benzamide
pH 5.0, 37ưC
0.00126
N-[(E)-[(4-methylphenyl)imino]methyl]benzamide
pH 5.0, 37ưC
0.00416
N-[(E)-[(4-nitrophenyl)imino]methyl]benzamide
pH 5.0, 37ưC
0.0014
N2-(morpholin-4-ylcarbonyl)-N-[(1E,3S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl]-L-leucinamide
-
-
0.0425
phenylacetyl hydrazine
0.263
(2E)-1,3-diphenylprop-2-en-1-one

pH 6.0, 37ưC
8.19
(2E)-1,3-diphenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 93.50% activity remaining
0.11
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one

pH 6.0, 37ưC
0.43
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 42.00% activity remaining
0.1
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one

pH 6.0, 37ưC
1.08
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 66.00% activity remaining
0.027
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one

pH 6.0, 37ưC, 1 mM, 0.30% activity remaining
0.312
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC
0.11
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one

pH 6.0, 37ưC
0.63
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 51.40% activity remaining
0.06
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one

pH 6.0, 37ưC
0.7
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 55.20% activity remaining
0.083
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one

pH 6.0, 37ưC
1.66
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 73.30% activity remaining
0.138
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one

pH 6.0, 37ưC
0.71
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 55.60% activity remaining
0.151
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one

pH 6.0, 37ưC
7.04
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 92.50% activity remaining
0.1
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one

pH 6.0, 37ưC
1
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37ưC, 1 mM, 61.80% activity remaining
0.0901
2-chlorobenzohydrazide

-
at pH 7.0 and 37ưC
0.0901
2-chlorobenzohydrazide
-
pH 5, 37ưC
0.588
2-methoxybenzohydrazide

-
at pH 7.0 and 37ưC
0.588
2-methoxybenzohydrazide
-
pH 5, 37ưC
0.0232
3,5-diphenyl-4-amino-1,2,4-triazole

-
at pH 7.0 and 37ưC
0.0232
3,5-diphenyl-4-amino-1,2,4-triazole
-
pH 5, 37ưC
0.1123
4-hydroxybenzohydrazide

-
at pH 7.0 and 37ưC
0.1123
4-hydroxybenzohydrazide
-
pH 5, 37ưC
0.0082
4-methoxybenzohydrazide

-
at pH 7.0 and 37ưC
0.0082
4-methoxybenzohydrazide
-
pH 5, 37ưC
0.000000095
chicken egg white cystatin

-
mutant T11_E18del-cathepsin H, pH 6.8, 30ưC
-
0.00000053
chicken egg white cystatin
-
wild type enzyme, pH 6.8, 30ưC
-
0.0032
N-benzoyl-3,5-diphenylpyrazoline

-
pH 7, 37ưC
0.0032
N-benzoyl-3,5-diphenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.00965
N-benzoyl-5-(2-methoxyphenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.00965
N-benzoyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.00144
N-benzoyl-5-(2-nitrophenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.00144
N-benzoyl-5-(2-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.00098
N-benzoyl-5-(3-nitrophenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.00098
N-benzoyl-5-(3-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.00127
N-benzoyl-5-(4-nitrophenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.00127
N-benzoyl-5-(4-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.000174
N-formyl-3,5-diphenylpyrazoline

-
pH 7, 37ưC
0.000174
N-formyl-3,5-diphenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.000135
N-formyl-5-(2-chlorophenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.000135
N-formyl-5-(2-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.000387
N-formyl-5-(2-methoxyphenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.000387
N-formyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.0000963
N-formyl-5-(2-nitrophenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.0000963
N-formyl-5-(2-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.00013
N-formyl-5-(3-chlorophenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.00013
N-formyl-5-(3-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.000272
N-formyl-5-(3-methoxyphenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.000272
N-formyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.0000519
N-formyl-5-(3-nitrophenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.0000519
N-formyl-5-(3-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.000137
N-formyl-5-(4-chlorophenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.000137
N-formyl-5-(4-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.000221
N-formyl-5-(4-methoxyphenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.000221
N-formyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.000058
N-formyl-5-(4-nitrophenyl)-3-phenylpyrazoline

-
pH 7, 37ưC
0.000058
N-formyl-5-(4-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37ưC
0.0425
phenylacetyl hydrazine

-
at pH 7.0 and 37ưC
0.0425
phenylacetyl hydrazine
-
pH 5, 37ưC
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.